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Introduction 
Basal cell carcinoma (BCC) is the most common non-melanoma 
skin cancer accounting for 80% of non-melanoma skin cancer 
(NMSCs) [1]. Worldwide incidence of BCC is increasing grad- 
ually by about 10% per annum [2]. The approximately 30% risk 
to develop BCC during lifetime of the Caucasian population. [3]. 
The most significant risk factor of BCC is genetic predisposi- 
tion and exposure to ultraviolet radiation (UVR) [4]. UVR in- 
fluence BCC development by DNA damaging and immunosup- 
pression [5]. UVB rays is primary established risk factor in  the 
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development of BCC and is a more potent and responsible cause 
of cutaneous damage and is believed to be the [6]. 
The typical BCC can be identified by pearly pink or shiny 
colored pa pule with telangiectasia or cystic nodule. Thus, a 
skin biopsy is performed for histopathologic analyses to diag- 
nose basal cell carcinomas. A shave biopsy is most common 
method under local anesthesia. BCC originate from basaloid ep- 
ithelia located in the bulges’ region of the hair follicle, in the 
epidermal stem cells of the outer root sheath and the follicular 
matrix cells, and in specific basaloid cells of the interfollicular 
epidermis [7]. BCC cells also express keratins type 5, 6 [8] and 
14 [9] and also α-2 and β-1 integrins [10]. BCC is an invasive 
epithelial skin tumor having stratum corneum of a median thick- 
ness of 0.3 mm [11]. Stratum corneum influence drug uptake and 
 
 
 
Ethosomal gel were prepared by using Carbopol.The viscosity was found to be in the range of 1600±1.72 to 1740±1.73 cps. 
Abstract 
Topical application of Itraconazole for the treatment of Basal cell carcinoma represents a new hope in dermatology. Itraconazole 
for treatment of Basal cell carcinoma is an alternative therapeutic approach for the efficacious treatment of non melanoma   
skin cancer. Itraconazole loaded ethosomes were prepared and characterized by vesicular shape, vesicular size, entrapment 
efficiency. Ethosomal gel were prepared and characterized by pH, viscosity, wash ability, spreadibility, drug content, drug release 
study, stability study, in vivo skin tolerability and antiproliferative activity. Transmission Electron Microscopy (TEM), and Dynamic 
Light Scattering (DLS) characterize ethosomes as spherical, unilamellar structures having low polydispersity (0.384 ± 0.037) and 
nanometric size range (169.0 ± 49.0), % Entrapment efficiency of Itraconazole in ethosomal carrier was found to be 82.00 ± 1.78. 
The spread ability was found to be in the range of 6.4g.cm/sec. The drug content of the ethosomal gel formulations ranged from
0.384-0.386 mg/gm. The value of steady-state trans dermal flux was observed to be 54.2 ± 1.46 µg/h/cm with a lag time of 1.2 
hrs with formulation EG1. Stability studies revealed no noticeable changes in drug release profile occurred. Skin irritation study 
on rabbit skin suggested that ethosomal gel may offer a suitable approach for trans dermal delivery of Itraconazole. The further, 
antiproliferative study shows that Itraconazole loaded ethosomes is significantly more toxic than the free drug on BCC1/KMC cell 
line, thus making it a potential alternative to the standard therapy 
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penetration into a tumor, therefore, affect the efficacy of topical 
treatment. 
Itraconazole widely uses asoral anti fungal drug. Now a day it 
has been proven that Itraconazole inhibits activation of the 
Hedgehog pathway therefore it has anti BCC activity. [12]. 
Hedgehog signal ling pathway is key promoter of BCC. Inhibi- 
tion of SMO activation by PTCH1 relieves by binding of Hedge- 
hog protein to PTCH1 receptor.SMO signaling occurs consti- 
tutively due to mutation in the PTCH1 receptor. Itraconazole 
directly interact with SMO lead to inhibition of expression of 
transcription factors glioma-associated (Gli) causes inhibition of 
SMO signaling. 
Transdermal drug delivery for BCC offers many advantages as 
compared to traditional drug delivery systems because it 
avoids systemic side effects and directly administered drug on 
the site of action. Transdermal drug delivery increases patient 
acceptability (non invasiveness), avoid gastrointestinal distur- 
bances which the drug permeates through various layers of skin, 
via a passive diffusion pathway. However, stratum corneum is 
the most formidable barrier to the passage of most of the drugs. 
Ethosomes have the potential of overcoming the skin barrier and 
have been reported to enhance permeability of drug through the 
stratum corneum barrier. 
Ethsomesare soft, malleable lipid vesicles made of water, 
phospholipids and alcohol (ethanol, isopropyl alcohol or polyol) 
in relatively high concentration(20-45%). Ethanol act as a per- 
meation enhancer and stabilizer. Ethanol fluidizes lipid bilayer 
of stratum corneum by intercalating into intercellular lipids and 
decreases the density of the lipid multi layer thus allowing the 
soft, malleable ethosomal vesicles to penetrate the disorganized 
lipid bilayer of stratum corneum [13]. Malleability of Ethoso- 
mal vesicles are increases because ethanol increases the fluidity 
of ethosomal lipids thus ethanol facilitate permeation of etho- 
somes smoothly inside the deep skin layers, where it got fused 
with skin lipids and releases the drugs into the deep layer of a 
tumor. 
The carbopol is a polymer of acrylic acid. It is a hydrophilic 
polymer and its volume increases in the presence of water be- 
cause it has a large amount of carboxyl groups on the poly-  
mer backbone ionize, resulting in repulsion between the neg- 
ative charges, which adds to the swelling of the polymer. The 
carbopol molecules change their configuration and increase the 
viscosity of the liquid in the presence of water and form a gel. 
Carbopol swell in water up to 1000 times of their original vol- 
ume to form a gel when exposed to a pH environment above 4.0 
to 6.0. Because the pKa of these polymers is 6.0 to 0.5. [14]. 
Carbopol polymers are very well suited to aqueous formulations 
of the topical dosage forms because it is safe & effective use in 
topical gels, creams, lotions, and ointments. It is non-sensitizing 
with repeat. Carbopol polymers provide an excellent vehicle for 
drug delivery due to their extremely high molecular weight, they 
cannot penetrate the skin or affect the activity of the drug. Car- 
bopol polymers have received extensive review and toxicologi- 
cal evaluation. Carbopol has been classified as Category 1 GRAS 
(Generally Recognized As Safe) materials. 
In this work, Itraconazole loaded ethosomal gel were pre- 
pared and characterized as a topical formulation for the treat- 
ment of BCC. Physicochemical and technological features of 
Itraconazole loaded ethosomal gel were investigated, and the 
anticancer activity of Itraconazole loaded ethosomal gel was as- 
sayed in comparison with the free drug both as cellular death and 
proliferation using a human skin BCC cell lines, which represent 
the malignant progression and differentiation of BCC [15]. 
 
Material  and Methods 
 
Materials 
Phospholipon 90G(PL-90G) (93.0 ± 3.0% phosphatidyl- 
choline), it was used without any purification. Absolute ethanol, 
Isopropanol, Itraconazole (HPLC purity P99%). RPMI-1640 
were purchased from Sigma Aldrich. BCC1/KMC cell  line 
was purchased by ATCC catalog no.TE 354. T (ATCC CRL- 
7762
TM 
). Double distilled pyrogen-free water was used through- 
out experimental investigations. Carbopol 934 were purchased 
from Sigma Aldrich, triethanolamine, phosphate buffer pH 6.8. 
All other materials were of analytical grade. 
 
Methods 
Preparation of ethosome 
Ethosomes were prepared by the cold method as reported and de- 
scribed earlier [16]. Briefly, ethosomal suspensions were made 
up of 2% w/v PL-90G and 30% absolute ethanol. PL-90G and 
Itraconazole were dissolved with absolute ethanol, and prepared 
lipid suspension was then hydrated with water, added slowly 
dropwise with help of micro pipette under a constant mixing 
with a magnetic stirrer at 700 rpm (Midi MR1 Digital IkamagR; 
IKA-WERKE). Prepared ethosomes were kept at room temper- 
ature for 30 min under continuous stirring (Orbital Shaker KS 
130 Control, IKA-WERKE). 
 
Ethosome size determination 
Mean size and size distribution of ethosomes were determined 
in triplicates at 25 ± 20 C using a Zetasizer Nano ZS (Malvern 
Instruments Ltd.) light scattering apparatus. Ethosomal sus- 
pension was diluted with the same ethanol/water volume ratio 
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used for their preparation, previously filtered through 0.22 µm 
polypropylene filter (Whatman, Clifford). Size distribution and 
mean size data of various ethosomal formulations are the mean 
of three different batches ± standard deviation. 
 
Ethosome shape and surface morphology determination 
Transmission Electron Microscope (TEM) (Philips CM12 Elec- 
tron Microscope) were used for ethosomal vesicles visualizing. 
Different formulations were centrifuged at 20,000 rpm for 90 
min at 4 0C by using an ultra centrifuge (RM-12C, Remi Pvt. 
Ltd.). Samples were dried on the carbon-coated grid and nega- 
tively impregnated with an aqueous solution of phosphotungstic 
acid. After drying the specimen was observed under the micro- 
scope at 10–100 k-fold enlargements at an accelerating voltage 
of 100 kV. 
 
Entrapment efficiency 
The entrapment efficiency of Itraconazole in ethosomes was 
evaluated using the ultracentrifugation method. Ethosomal sus- 
pensions (1 ml) were transferred into 2 ml polypropylene cen- 
trifuge tube and centrifuged at 20,000 rpm for 90 min at 4      
0C by using an ultra centrifuge (PR-23, Remi Pvt. Ltd.). The 
supernatant was separated from the pellet and analyzed by 
using high performance liquid chromatography (HPLC) (LC- 
2010HT, Shimadzu Pvt. Ltd.) apparatus than pellet was dis- 
solved in cold methanol (HPLC grade) and immediately ana- 
lyzed by HPLC [17]. The entrapment efficacy (EE) of ethosomes 
was expressed according to the following equations: 
% EE = [DT   — DS ] / DT   × 100 
And 
% EE = [DE  / DT ] × 100 
Where, DT is the total amount of drug was added during the 
preparation of ethosomes, DS is the amount of drug was deter- 
mined in the supernatant, and DE is the amount of drug encapsu- 
lated in the ethosomal pellet. The values of entrapment efficiency 
obtained using the two different equations differed by less than 
3%. 
 
Preparation of ethosomal gel 
On the basis of the results of ethosomal vesicle evaluation, the 
best achieved ethosomal vesicles formulation was prepared into 
gel formulation by incorporated into carbopol gel (1%, 1.5%, 
2% w/w). The carbopol 934 powder was slowly added to dis- 
tilled water and kept at 1000C for 20 min and triethanolamine 
was added to it drop wise as shown in table 1. [18] 
Measurement of pH 
The values of pH of all the ethosomalgel formulations were mea- 
sured by using digital pH meter (ELICO.LI 610 pH meter) at the 
room temperature. 1gm of gel dissolved in 30ml of distilled wa- 
ter (pH 7.0). A glass rod was dipped into solution of ethosomal 
gel in a beaker. The readings were taken for average of 3 times. 
[16] 
 
Measurement of Viscosity 
The viscosity of the developed ethosomal gel formulations were 
determined by using 
A Brookfield digital viscometer (Model DV-II, USA) equipped 
with spindle V-72. The apparent viscosity was mea- sured at 
shear rate 50 rpm at room temperature, after a 3-min rest time. 
[18] 
 
Wash ability 
A small quantity of gel was applied on the skin and washed with 
water in order to check the wash ability of gel. 
Spreadability 
Spreadability of gel was determined by using modified wooden 
block and glass slide apparatus. A measured amount of ethoso- 
mal gel was placed on fixed glass slide; the movable pan with a 
glass slide attached to it and was placed over the fixed glass slide, 
such that the gel was sandwiched between the two glass slides 
for 5min. The weight was continuously removed. Sp readability 
was determined using the formula. [19] 
S = M/T 
Where, S is the Spreadability in g/s, M is the mass in grams & 
T is the time in seconds. 
 
Drug content 
One gram of ethosomal gel was dissolved in a100 ml of phos- 
phate buffer pH 6.8 stirred constantly for 2 days by using mag- 
netic stirrers. The resultant solution was filtered and content was 
analysed by U. V spectrophotometer. The release profiles of Itra- 
conazole loaded ethosomes were measured using vertical 
 
Drug release study 
Franz diffusion cells (EMFDC-06, Orchid scientific Pvt. Ltd.) 
having a receptor compartment with a nominal volume of 4.75 
ml, a diffusion surface membrane area of 0.75 cm2, and a donor 
compartment having a maximum volume of 2 ml. A synthetic 
poly carbonate membrane with a molecular cut-off of 20,000 
daltons was placed between donor compartment and receptor 
compartments. Ethosomal gel of 200 µl was added to the donor 
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Table 1 Composition ofdifferent ethosomal gel formulation 
 
Gel formulation Itraconazole loaded ethosomal suspension (ml) Carbopol 934 
(% w/w) 
Triethanolamine 
(ml) 
Phosphate buffer 
(pH 6.8) 
EG1 20 1 0.5 q.s. 
EG2 20 1.5 0.5 q.s. 
EG3 20 2 0.5 q.s. 
compartment, and the receptor was filled up with phosphate 
buffer of pH 6.8 at the same v/v ratio used for the preparation 
of the different vesicular colloidal systems. The receptor fluid 
was stirring continuously at 600 rpm using a magnetic anchor (1 
mm length), and the temperature kept at 37.0 ± 0.5 0C. [20] 
The experiment was carried out up to 24 hrs, and 1 ml of   the 
receptor fluid was withdrawn at predetermined times using a 
syringe and then immediately replaced with the same volume 
of fresh fluid. These samples were immediately analyzed by 
HPLC (LC-2010HT, Shimadzu Pvt. Ltd.). The experiment was 
performed in triplets and results were expressed as the average 
of three different experiments ± standard deviations. [21] 
The release kinetics of Itraconazole loaded ethosomes were 
determined by the best fit of the experimental data by applying 
the Higuchi release model equation: 
 
and hair at the back was trimmed short, 24 h before the begin- 
ning of assay. The animals were divided in two groups of six 
each. First, groups received ethosomal gel and the second group 
was control (0.9% w/w NaCl solution). Each rabbit subjected to 
draw three squares on each side of the back, and 200 µl formula- 
tion was applied on each square. The test substance was removed 
after exposure for 32 h, and exposed skin was scored depending 
on the degree of erythema, as follows: no erythema — 0, very 
slight erythema (light pink) — 1, well-defined erythema (dark 
pink) — 2, moderate to severe erythema (light red) — 3. 
 
Anti-proliferative activity 
The cytotoxicity of Itraconazole loaded ethosomal vesicle was 
determined by MTT assay in BCC1/KMC cell line on 96-well 
plates. Cells were seeded in a dilution rate of 1 × 104 each well 
Mt / M∞ = Kh t1/2 
at 370C and 5 % CO2  by using RPMI-1640 medium contain- 
ing 10 % fetal bovine serum and 1 % penicillin/streptomycin. 
Where, Mt is the fraction of drug released at each time points 
(t), M∞ is the total amount of drug present in ethosomal suspen- 
sion and Khrepresents the Higuchi release kinetic constant. This 
equation can be simplified for a zero-order release kinetic in the 
following form: 
Mt  / M∞ = K0 t 
  where   K0representsthezero−orderreleasekineticconstant. 
 
Stability Studies 
Stability study was carried out for ethosomal gel preparation at 
two different temperature i.e. refrigeration temperature (4 ± 2◦ 
C) room temperature (27 ± 2◦ C, RH ± 5 RH) for 8 weeks 
(as per ICH guidelines). The gel formulation was subjected to 
stability study and stored in borosilicate container to avoid any 
sort of interaction between the ethosomal gel preparation and 
glass of container, which may affect the observations. Sample 
was collected for every 2 weeks and content was analyzed at 
262 nm in U. V spectrometer. 
 
Skin irritancy studies 
The skin irritancy or erythema potential of ethosomes, was eval- 
uated as reported elsewhere [22]. Briefly, skin irritancy of the 
formulation was determined in male albino rabbits (1.9–2.0 kg). 
The animals were housed at 200C in an air-conditioned room 
They were allowed to attach for 48 h. Thereafter culture media 
was removed and cells were treated with free Itraconazole and 
ethosome loaded Itraconazole at concentrations of 6.383, 3.596, 
1.585, 0.792, 0.391 and 0.162 µM. The drug-containing culture 
was removed after 24 hrs and 80 µL MTT solutions (0.5 mg/mL, 
pH 7.4) was added to each well and incubated for 2 hrs Later, 
MTT was discarded and to dissolve the formazan crystals, 100 
µl isopropanol 100 % was added. Finally, absorbance was read 
at 540 nm in an Elisa reader (Bio Tek Instruments). IC50 was 
measured by statistical package Pharm-PCS software. 
 
Results  & Discussion 
 
Preparation and evaluation of Ethosomes 
Ethosomes were prepared by cold methods having vesicle size 
169.0 ± 49.0 nm shows ethosomes had optimum size. Dynamic 
light scattering analysis showed that physicochemical properties 
including mean size, size distribution, and zeta-potential were 
depended on the composition of the vesicle. Ethanol and PL 
90G influenced vesicular size distribution. Experimental find- 
ings showed that a narrow size distribution with a polydispersity 
index (PDI) of 0.384 ± 0.037 was obtained for ethosomalvesi- 
cles. Prepared ethosomes were shown 82.00 ± 1.78 % of drug 
entrapped inside the vesicles this is good percent of drug  pene- 
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tration. Prepared ethosomes were examined by TEM appeared as 
unilamellar vesicles with a predominant spherical shape (Figure 
1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Preparation and evaluation of ethosomal gel 
Itraconazole loaded ethosomal gel have been prepared and eval- 
uated for following parameters. 
 
Measurement of pH 
The pH measurement of the developed ethosomal gel carried 
out by using digital pH meter at room temperature. Results are 
shown in Table 2. The pH value of the developed ethosomal gel 
was found to be in the range of 6.80±0.05 to 6.84±0.08 which 
demonstrate that the prepared gels will irritation free to the skin. 
 
Viscosity 
The viscosity measurement results of the developed ethosomal 
gel, carried out by using Brookfield digital viscometer at room 
temperature. The results are shown in Table 2. The viscosity of 
the developed ethosomal gel was found to be in the range of 
1600±1.72 to 1740±1.73 cps. 
Washability 
Drug content 
The drug content of the ethosomal gel formulations ranged from 
0.384-0.386 mg/gm. The values obtained from the drug content 
are shown in Table 2, it was concluded that there was no loss of 
drug during the gel preparation process. 
 
Table 2  Results of ethosomalgel evaluation. 
 
 
 
 
0.16 
 
0.51 
 
0.46 
 
 
Values represent means ± SD (n = 3). 
 
Drug release study 
Experimental findings showed that Itraconazole loaded ethoso- 
mal gel (formulation EG2) permeated through the dialysis mem- 
branes faster than the Itraconazole suspension. The ability of 
ethosomal gel to deliver Itraconazole was investigated by de- 
termining the flux of Itraconazole across dialysis membrane. 
The cumulative amount of Itraconazole permeated per unit area 
across dialysis membrane via formulation E5 was plotted as a 
function of time (Figure 2). The value of steady-state transder- 
mal flux for Itraconazole loaded ethosomal formulation was ob- 
served to be 54.2 ± 1.46 µg/h/cm with a lag time of 1.2 hrs with 
formulation EG1 and 51.3 ± 1.46 µg/h/cm with a lag time of 
1.22 hrs with formulation EG2. 
  Kinetic analysis of release mechanism 
The drug release data of optimized formulation EG1 and EG2 
were fitted to models representing Higuchi’s, zero order, first or- 
der, Banker - lonsdale and Korsmeyer’s- peppas equation kinet- 
ics to know the release mechanisms with the help of software 
Sigma plot (v12). 
Where, 
Qt: Amount of drug released in time t 
Q0: Initial amount of drug in the tablet 
k , K , K   , Ks: release rate  constants 
0 1 H 
Prepared ethosomal gel is easily washable without leaving any 
residue on thesurface of the skin. 
 
Spreadability 
The spreadability of the ethosomal gels was found to be in     
the range of 6.4g.cm/sec reveal that its spread smooth and uni- 
formly. 
n: Release exponent (indicative of drug release mechanism) 
W: Initial amount of drug in dosage form, 
Wt: Remaining amount of drug in dosage form at time t 
Ks: A constant incorporating the surface–volume relation. 
It was observed that the correlation coefficient values are higher 
(r2  = 0.97) with Higuchi model. Higuchi proposed this 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Visualization of ethosomesby Transmission Electron 
Microscopy (X 1,10,000). 
Formula- 
tion 
pH Viscosity 
(CPS) 
Drug content 
(mg/gm) 
EG1 
EG2 
EG3 
6.83 ± 
6.80 ± 
6.84 ± 
1600 ± 1.72 
1689 ± 1.45 
1740 ± 1.68 
0.384 ± 0.021 
0.386 ± 0.016 
0.386 ± 0.034 
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Table 3 Equation and obtainedregression coefficient value for different model. 
 
Sr. no. Model Equation R2 for EG1 R2 for EG2 
1 Zero order Qt= Q0 + K0t 0.9231 0.9215 
2 First order ln Qt= ln Q0 – K1t 0.8124 0.8023 
3 Hixson–Crowell W01/3 – Wt1/3 = Ks t 0.8164 0.8026 
4 Higuchi Qt= KH  t1/2 0.9902 0.9834 
5 Korsmeyer–Peppas Qt /Q∞ = Kk tn 0.6315 0.6234 
6 Baker–Lonsdale (3/2) [1- (-1( Qt/Q∞))2/3 ] - ( Qt/Q∞) = K t 0.6315 0.6146 
 
 
model in 1961 to describe the drug release from matrix system. 
Higuchi model is based on the hypotheses that: 
Initial drug concentration in the matrix is much greater than 
drug solubility 
Drug diffusion is taking place only in one dimension (edge 
effect must be negligible). 
       Drug particles are much smaller than system thickness. 
       Matrix swelling and dissolution are in negligible level. 
       Drug diffusivity is constant. 
perfect sink conditions are always attained in the release 
environment. 
Higuchi model can be written as: 
ft = Q = KH.t1/2 
where, 
KH  is the Higuchi dissolution constant 
The data obtained were plotted as cumulative percentage drug 
release versus square root of time. 
On comparing the release kinetics data (Table 4), formulation 
EFG1 were found to release the drug in accordance to Higuchi 
Kinetics which were indicated by the highest correlation coeffi- 
cient values. 
Stability Studies 
The ability of vesicles to retain the drug was assessed by keep- 
ing the ethosomal gel formulation at different temperature. Op- 
timized ethosomal gel formulation (EG1) were selected for sta- 
bility studies. Ethosomal gel formulations were observed for any 
change in appearance for a period of 8 weeks showed no notice- 
able changes in drug release profile occurred. It was concluded 
that the ethosomal gel system is more stable at specified storage 
conditions. 
 
Skin irritation Studies 
Skin tolerability/irritancy is an important characteristic to be 
evaluated before the proposal of a drug carrier as a potential 
transdermal drug delivery system. Measurement of erythema 
scores upon exposure of hairless rabbit skin of ethosomal for- 
mulations and saline solution (0.9% w/w NaCl solution, control) 
revealed that saline and ethosomes showed no significant ery- 
thema (Table 5),demonstrating that ethanol present in the etho- 
somal formulation is unable to act as a skin erythema inducing 
agent, even though present in high concentration. 
  Values represent means ± SD (n = 3). 
 
Anti proliferative studies 
MTT assay is a valid test to evaluate the efficacy of the ethoso- 
mal formulation in vitro , and hence it was used in the present 
study to assess the cytotoxicity of Itraconazole on BCC1/KMC 
cell line. The ethosomal formulation decreased cell viability by 
34 % compared with the free-form. The results showed the IC50 
of ethosomal formulation for BCC1/KMC cell line is less than 
that of the standard drug. Based on the definition of IC50 (8.2 
free drugs against 1.8 of the ethosomal formulation), the cy- 
totoxicity of the ethosomal formulation against BCC1/KMC is 
about 4.6 times of that of the free drug. 
 
Conclusions 
The current investigation revealed that Itraconazole loaded etho- 
somal gel provided an enhanced trans dermal flux, lower lag 
time, good entrapment efficiency and low skin irritant potential. 
The ethosomal formulated drug penetrate more deeper and more 
effectively kill cytotoxic cells. Ethosomal gel incorporated drug 
has a longer half-life and stronger cytotoxic effect than the free 
drug form. Topical penetration of drug enhances thus, leading 
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Table 4 Release rate constant(k) and correlation coefficient (R2) of formulation EG1 and EG2. 
Sr. no. Gel formulation Zero order kinetics First order kinetics Higuchi kinetics 
 
k R2 k R2 k R2 
1. EG1 2.156 0.946 1.82 0.953 0.435 0.932 
2. EG2 1.864 0.916 1.24 0.931 0.386 0.895 
 
Table 5  Erythema scores of formulations 
 
Rabbit no. Erythema scores  
 Saline solution Ethosomes 
1 0 1 
2 0 1 
3 0 1 
4 0 0 
5 1 1 
6 0 0 
Average score 0.16 0.66 
 
 
 
to the generic conclusion that this approach offers a suitable ap- 
proach for trans dermal delivery of Itraconazole. 
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